RECEIVED

7

71

SEP 2 0 2002

CLARK & ELBING

ACTION DUE OF TICHAL ART. 19 HOURS.

DUE DATE 11-13-59

INITIALS 7-M-JALLE

CLARK & ELBING LLP Attn. Bieker-Brady, Kristina 176 Federal Street Boston, MA 02110-2214 UNITED STATES OF AMERICA

Date: 12/09/2002

RECEIVED

NOV 0 7 2002

TECH CENTER 1600/2900

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

PCI

To: CLARK & ELBING LLP Attn. Bieker-Brady, Kristina 176 Federal Street Boston, MA 02110-2214 UNITED STATES OF AMERICA

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

176 Federal Street Boston, MA 02110-2214 UNITED STATES OF AMERICA	(PCT Rule 44.1)
	Date of mailing (day/month/year) 12/09/2002
Applicant's or agent's file reference 01948/074W02	FOR FURTHER ACTION See paragraphs 1 and 4 below
International application No. PCT/US 01/19670	International filing date (day/month/year) 19/06/2001
Applicant BETH ISRAEL DEACONESS MEDICAL CENTER	
Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the clai When? The time limit for filing such amendments is norm international Search Report; however, for more of the international Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Fascimile No.: (41–22) 740.14.3 For more detailed instructions, see the notes on the account of the applicant is hereby notified that no International Search Article 17(2)(a) to that effect is transmitted herewith. 3. With regard to the protest against payment of (an) additing the protest together with the decision thereon has be	nally 2 months from the date of transmittal of the letails, see the notes on the accompanying sheet.
no decision has been made yet on the protest; the a	pplicant will be notified as soon as a decision is made.
4. Further action(s): The applicant is reminded of the following Shortly after 18 months from the priority date, the international If the applicant wishes to avoid or postpone publication, a noti priority claim, must reach the International Bureau as provide completion of the technical preparations for international publi Within 19 months from the priority date, a demand for international wishes to postpone the entry into the national phase until 30 m Within 20 months from the priority date, the applicant must perform all designated Offices which have not been elected in priority date or could not be elected because they are not bound.	application will be published by the International Bureau. ce of withdrawal of the international application, or of the d in Rules 90bis.1 and 90bis.3, respectively, before the cation. Onal preliminary examination must be filed if the applicant nonths from the priority date (in some Offices even later). Form the prescribed acts for entry into the national phase the demand or in a later election within 19 months from the
Land Was address of the International Conseling Authority	A. Al-ada-da-Wissa

Ī	Name and mailing address of the International Searching Authority	Authorized officer
	European Patent Office, P.B. 5818 Patentiaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	
ı	Fax: (+31-70) 340-3016	

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international polication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been its filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (c ntinued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- [Where originally there were 48 claims and after amendment of some claims there are 51]:
 *Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers;
 claims 30, 33 and 36 unchanged; new claims 49 to 51 added.*
- [Where originally there were 15 claims and after amendment of all claims there are 11]:
 "Claims 1 to 15 replaced by amended claims 1 to 11."
- [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
 "Claims 1.to.6 and 14 unchanged; claims 7.to.13 cancelled; new claims 1.5, 16 and 17 added." or "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- 4. [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international appplication is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference		of Transmittal of International Search Report 20) as well as, where applicable, item 5 below.
01948/074W02	ACTION	20) as well as, where applicable, item 5 below.
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/US 01/19670	19/06/2001	19/06/2000
Applicant		
DETU TODACI DEACONESS MED	TCAL CENTED	
BETH ISRAEL DEACONESS MED	ICAL CENTER	
This International Search Report has bee according to Article 18. A copy is being tr	n prepared by this International Searching Autl	nority and is transmitted to the applicant
3		
This International Search Report consists		
X It is also accompanied by	a copy of each prior art document cited in this	s report.
Basis of the report		
 a. With regard to the language, the language in which it was filed, un 	international search was carried out on the balless otherwise indicated under this item.	sis of the international application in the
the international search w Authority (Rule 23.1(b)).	vas carried out on the basis of a translation of t	the international application furnished to this
b. With regard to any nucleotide an	nd/or amino acid sequence disclosed in the in	nternational application, the international search
was carried out on the basis of th contained in the internation	e sequence listing : onal application in written form.	
filed together with the inte	ernational application in computer readable for	m.
(X) furnished subsequently to	this Authority in written form.	
=	this Authority in computer readble form.	
the statement that the sul international application a	bsequently furnished written sequence listing on the sequence listing of the s	does not go beyond the disclosure in the
the statement that the info	ormation recorded in computer readable form	is identical to the written sequence listing has been
2. X Certain claims were fou	ind unsearchable (See Box I).	
3. Unity of invention is lac	king (see Box II).	
4. With regard to the title,		
the text is approved as su	ubmitted by the applicant.	
the text has been establis	shed by this Authority to read as follows:	
5. With regard to the abstract,		
X the text is approved as su	• • •	
	shed, according to Rule 38.2(b), by this Autho e date of mailing of this international search re	rity as it appears in Box III. The applicant may, eport, submit comments to this Authority.
6. The figure of the drawings to be pub	lished with the abstract is Figure No.	1
X as suggested by the appl	icant.	None of the figures.
because the applicant fai	led to suggest a figure.	
because this figure better	characterizes the invention.	
1		

International Application No PCT/US 01/19670

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 CO7K16/28 C12M C12N5/08 C07K16/46 C12N5/20 G01N33/53 GO1N33/577 G01N33/68 A61K39/395 A61K47/48 A61K51/10 A61P31/00 A61P11/06 A61P35/00 A61K35/14 A61P37/00 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) BIOSIS, EPO-Internal, WPI Data, PAJ, SEQUENCE SEARCH C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Category ° Relevant to claim No. WO 99 34209 A (BRIGHAM & WOMENS HOSPITAL) 1.5 - 8.X 8 July 1999 (1999-07-08) 14-17-20,31,32, 39-42 page 6, line 5 -page 7, line 11 page 7, line 24-29 page 8, line 14 claims 8-10 Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: *T* later document published after the international filing date or priority date and not in conflict with the application but "A" document defining the general state of the art which is not considered to be of particular relevance cited to understand the principle or theory underlying the invention *E* earlier document but published on or after the international *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-O document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled in the art. other means document published prior to the international filing date but later than the priority date claimed *&* document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search 6 September 2002 12/09/2002 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, COVONE-VAN HEES, M Fax: (+31-70) 340-3016

4

International Application No PCT/US 01/19670

A. CLASSI IPC 7	FICATION OF SUBJECT MATTER A61P15/00	·	
According to	o International Patent Classification (IPC) or to both national classifica	tion and IPC	
B. FIELDS	SEARCHED		
Minimum do	cumentation searched (classification system followed by classification	n symbols)	
Documentat	ion searched other than minimum documentation to the extent that su	uch documents are included in the fields se	arched
Electronic d	ata base consulted during the international search (name of data bas	e and, where practical, search terms used)	
C. DOCUMI	ENTS CONSIDERED TO BE RELEVANT		······
Category °	Citation of document, with Indication, where appropriate, of the rele	evant passages	Relevant to claim No.
X	EXLEY MARK ET AL: "CD161 (NKR-P1 costimulation of CD1d-dependent a of human T cells expressing invar Valpha24JalphaQ T cell receptor a chains." JOURNAL OF EXPERIMENTAL MEDICINE, vol. 188, no. 5, pages 867-876, XP001074739 ISSN: 0022-1007 page 868, left-hand column, line -right-hand column, line 14 table 1	ctivation iant lpha	1,2,5, 7-17,23, 39-42
X Furti	her documents are listed in the continuation of box C.	χ Patent family members are listed	in annex.
'A' docume consic 'E' earlier of filing of the docume which citation 'O' docume other of the docume later the docume later the docume later the docume considered the docume later the later the docume later the docume later the docume later the later the later t	ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international late the state of	*T* later document published after the inte or priority date and not in conflict with cited to understand the principle or the invention *X* document of particular relevance; the cannot be considered novel or canno involve an inventive step when the document of particular relevance; the cannot be considered to involve an in document is combined with one or ments, such combination being obvious in the art. *&* document member of the same patent Date of mailing of the international see	the application but early underlying the stairmed invention to considered to coursent is taken alone claimed invention ventive step when the ore other such docu-us to a person skilled
L	nailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2	Authorized officer	
	NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	COVONE-VAN HEES,	M

International Application No
PCT/US 01/19670

		FC1/03 01/196/0
C.(Continua Calegory °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NICOL A ET AL: "Human invariant Valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells." IMMUNOLOGY., vol. 99, no. 2, February 2000 (2000-02), pages 229-234, XP001073724 ISSN: 0019-2805 abstract page 229, left-hand column, paragraph 1 -right-hand column, paragraph 1 page 230, right-hand column, paragraphs 2,3	1,2,7,8, 12-17
Х	EP 0 677 533 A (MILTENYI STEFAN) 18 October 1995 (1995-10-18) column 3, line 50 -column 4, line 6	9-11
<u></u> .	claims	
Ρ,Χ	EP 1 025 854 A (GSF FORSCHUNGSZENTRUM UMWELT) 9 August 2000 (2000-08-09) column 2, line 58 -column 3, line 6 example 1 figure 1	1,3,5,7, 20-23
T	WILSON S BRIAN ET AL: "Development of monoclonal antibodies to Valpha24JalphaQ T cells detects alterations in cell frequency in new-onset type 1 diabetes patients." DIABETES, vol. 50, no. Supplement 2, June 2001 (2001-06), page A267 XP008004082 61st Scientific Sessions of the American Diabetes Association; Philadelphia, Pennsylvania, USA; June 22-26, 2001 ISSN: 0012-1797 abstract	1-42

International application No. PCT/US 01/19670

INTERNATIONAL SEARCH REPORT

Box I Observations where certain claims wer found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 20-22,31-38 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

Information on patent family members

International Application No
PCT/US 01/19670

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9934209	Α	08-07-1999	AU WO	2087799 A 9934209 A1	19-07-1999 08-07-1999
			US 	6162609 A 	19-12-2000
EP 0677533	Α	18-10 - 1995	CA EP	2146693 A1	13-10-1995
			JP	0677533 A2 8056692 A	18-10-1995 05-03-1996
EP 1025854	 , А	09-08-2000	DE	19905048 A1	10-08-2000
			EP	1025854 A1	09-08-2000

Form PCT/ISA/210 (patent family annex) (July 1992)